Holen Sie sich die Stockscreener-App
3.8488
19.07%
0.6088
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Zentalis Pharmaceuticals Inc (ZNTL)’s highs and lows: A closer look at its stock price fluctuations - US Post News
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers - Yahoo Finance
FDA lifts hold on Zentalis cancer drug trials - Investing.com India
Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies - Marketscreener.com
Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies - MarketWatch
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies - StockTitan
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies - GlobeNewswire
TD Asset Management Inc Decreases Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $11.33 Consensus PT from Brokerages - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Recommendation of “Hold” from Analysts - Defense World
A Look at Zentalis Pharmaceuticals Inc (ZNTL) Shares in the Recent Past Indicates Growth - SETE News
Technical analysis of Zentalis Pharmaceuticals Inc (ZNTL) stock chart patterns - US Post News
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers - AOL
Zentalis Pharmaceuticals Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Ratios Uncovered: Breaking Down Zentalis Pharmaceuticals Inc (ZNTL)’s Trailing Twelve Months Metrics - The Dwinnex
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024 - GlobeNewswire
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024 - StockTitan
Zentalis Pharmaceuticals Inc [ZNTL] Records 200-Day SMA of $10.46 - Knox Daily
Zentalis Pharmaceuticals Inc (ZNTL)’s stock decline to 3.23 per share - US Post News
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Zentalis Pharmaceuticals Inc (ZNTL) Stock: A Year of Market Fluctuations - The InvestChronicle
Analyzing Zentalis Pharmaceuticals Inc (ZNTL) After Recent Trading Activity - Knox Daily
Market Insight: Zentalis Pharmaceuticals Inc (ZNTL)’s Notable Drop, Closing at 3.18 - The Dwinnex
Are Smart Investors Making the Right Decision? Zentalis Pharmaceuticals Inc (ZNTL) - SETE News
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why - Zacks Investment Research
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why - Yahoo Finance
ZNTL (Zentalis Pharmaceuticals Inc) has impressive results - US Post News
It is Poised to be a Bull Market for Zentalis Pharmaceuticals Inc (ZNTL) - SETE News
Company’s Banking Stock: Dissecting a -73.37% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Analysts Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Price Target at $11.33 - MarketBeat
Investigation announced for Investors who lost money with shares of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) - openPR
ZNTL (Zentalis Pharmaceuticals) EPS (Basic) : $-2.72 (TTM As of Jun. 2024) - GuruFocus.com
Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL - Business Wire
What was Zentalis Pharmaceuticals Inc (ZNTL)’s performance in the last session? - US Post News
Quarterly Metrics: Quick and Current Ratios for Zentalis Pharmaceuticals Inc (ZNTL) - The Dwinnex
ZNTL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Clients to Contact the Firm! - AccessWire
Zentalis Pharmaceuticals Inc (ZNTL) Stock: Navigating a Year of Volatility - The InvestChronicle
Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: - GlobeNewswire
HC Wainwright Analysts Cut Earnings Estimates for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - GlobeNewswire Inc.
Q3 2024 EPS Estimates for Zentalis Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm - AccessWire
ZNTL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Today! - AccessWire
Q3 2024 EPS Estimates for Zentalis Pharmaceuticals, Inc. Raised by Wedbush (NASDAQ:ZNTL) - MarketBeat
Zentalis Pharmaceuticals, Inc. Expected to Earn Q3 2024 Earnings of ($0.86) Per Share (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm - AccessWire
ZNTL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Today! - AccessWire
A significant driver of top-line growth: Zentalis Pharmaceuticals Inc (ZNTL) - SETE News
Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - Business Wire
Zentalis Pharmaceuticals Inc Investors Invited To Join Fraud Investigation With Schall Law Firm - AccessWire
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Buy Rating from HC Wainwright - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Rating Reiterated by HC Wainwright - Defense World
The Zentalis Pharmaceuticals Inc (ZNTL) Stock Is Headed for a Correction - US Post News
Market Recap: Zentalis Pharmaceuticals Inc (ZNTL)’s Negative Momentum, Closing at 3.00 - The Dwinnex
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Upgraded to "Neutral" by Wedbush - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Rating Upgraded by Wedbush - Defense World
ZNTL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Stockholders to Contact the Firm! - AccessWire
Zentalis Pharmaceuticals Slides As Insider Purchases Lose Another US$153k - Simply Wall St
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Announces Quarterly Earnings Results - Defense World
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Issues Quarterly Earnings Results, Misses Estimates By $0.40 EPS - MarketBeat
Zentalis Pharmaceuticals Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm - AccessWire
1.26%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):